Management of ascites in cirrhosis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 12, Issue 11, 1997, Pages 723-733

  Bataller, Ramon ^a   Arroyo, Vicente ^a,b   Ginès, Pere ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Ascites; Cirrhosis; Portal hypertension; Renal failure

Indexed keywords

DIURETIC AGENT;

ARTERY DILATATION; ASCITES; BED REST; HEART OUTPUT; HUMAN; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PARACENTESIS; PERITONEUM VEIN SHUNT; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SODIUM RESTRICTION;

EID: 0030730147     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1997.tb00360.x     Document Type: Review

References (91)

1. Ginès P, Quintero E, Arroyo V et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987; 7: 122-8.
2. Bataller R, Ginès P, Guevara M, Arroyo V. Hepatorenal syndrome. Semin. Liver Dis. 1997(in press).
3. Le Veen HH, Christoudias G, Ip M et al. Peritoneovenous shunting for ascites. Ann. Surg. 1974; 180: 580-91.
4. Ginès P, Arroyo V, Quintero E et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology 1987; 93: 234-41.
5. Quiroga J, Sangro B, Nuñez M et al. Transjugular portal-systemic shunt in the treatment of refractory ascites: effect on clinical, renal, humoral, and hemodynamic parameters. Hepatology 1995; 21: 986-94.
6. Siuta M, Sanyal AJ, Schubert ML. Tips for the treatment of refractory ascites. Gastroenterology 1996; 110: 956-8.
7. Bosch J, Arroyo V, Betriu A et al. Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis. Gastroenterology 1980; 78: 92-9.
8. Schrier RW, Arroyo V, Bernardi M et al. Peripheral arteriolar vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 1151-7.
9. Arroyo V, Ginès P. Arteriolar vasodilation and the pathogenesis of the hyperdynamic circulation and renal sodium and water retention in cirrhosis. Gastroenterology 1992; 102: 1077-9.
10. Ring Larsen H, Henriksen JH, Wilken C et al. Diuretic treatment in decompensated cirrhosis and congestive heart failure: effects of posture. BMJ 1986; 292: 1351-3.
11. Saló J, Ginès A, Anibarro L et al. Effect of upright posture and physical exercise on endogenous neurohormonal systems in cirrhotic patients with sodium retention and normal supine plasma renin, aldosterone, and norepinephrine levels. Hepatology 1995; 22: 479-87.
12. Arroyo V, Ginès P. Treatment of ascites in cirrhosis. Diuretics, peritoneovenous shunt and large-volume paracentesis. Gastroenterol. Clin. North. Am. 1992; 21: 237-56.
13. Ginès P, Arroyo V, Rodés J. Pharmacotherapy of ascites associated with cirrhosis. Drugs 1992; 43: 316-32.
14. Ginès P, Arroyo V, Rodés J. Disorders of renal function in cirrhosis: pathophysiology and clinical aspects. In: Zakim D, Boyer TD, eds. Hepatology: A Textbook of Liver Disease, 3rd edn. Philadelphia: WB Saunders, 1996; 650-74.
15. Olind B. Relationship between renal tubular excretion and effects of fire loop diuretics. J. Pharm. Exp. Ther. 1979; 211: 238-44.
16. Planas R, Arroyo V, Rimola A et al. Acetylsalicylic acid suppresses the renal hemodynamic effect and reduces the diuretic action of furosemide in cirrhosis with ascites. Gastroenterology 1983; 84: 247-52.
17. Pinzani M, Daskalopopulos G, Laffi G et al. Altered furosemide pharmacokinetics in chronic alcoholic liver disease with ascites contributes to diuretic resistance. Gastroenterology 1987; 922: 294-8.
18. Gatta A, Angeli P, Caregaro L et al. A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients. Hepatology 1991; 14: 231-6.
19. Pérez-Ayuso RM, Arroyo V, Planas R et al. Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Gastroenterology 1983; 84: 961-8.
20. Laffi G, Marra F, Buzzelli G et al. Comparison of the effects of torasemide and furosemide in nonazotemic cirrhotic patients with ascites: A randomized double-blind study. Hepatology 1991; 13: 1101-5.
21. Sungaila I, Bartle WR, Walker SE et al. Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites. Gastroenterology 1992; 102: 1680-5.
22. Sherlock S, Senewiratne B, Scot A, Walker JG. Complications of diuretic therapy in hepatic cirrhosis. Lancet 1966; 1: 1049-53.
23. Strauss RM, Boyer TD. Diagnosis and management of cirrhotic ascites. In: Zakim D, Boyer T, eds. Hepatology: A Textbook of Liver Disease, 3rd edn. Philadelphia: WB Saunders, 1996; 764-90.
24. Pockros PJ, Reynolds TB. Rapid diuresis in patients with ascites from chronic liver disease: the importance of peripheral edema. Gastroenterology 1986; 90: 1827-33.
25. Shear L, Ching S, Gabuzda GJ. Compartmentalization of ascites and edema in patients with hepatic cirrhosis. N. Engl. J. Med. 1970; 282: 1391-6.
26. Bernardi M, Servadei D, Treviasani F et al. Importance of plasma aldosterone concentration on the natriuretic effect of spironolactone in patients with liver cirrhosis and ascites. Digestion 1985; 31: 189-93.
27. Campollo O, McGillivray BB, McIntyre N. Association of plasma ammonia and GABA levels and the degree of hepatic encephalopathy. Rev. Invest, Clin. 1992; 44: 483-90.
28. Blei AT. Advances in the treatment of hepatic encephalopathy. In: Arroyo V, Bosch J, Rodés J, eds. Treatments in Hepatology. Barcelona: Masson, 1995; 81-5.
29. Loriaux DL, Menard R, Taylor A et al. Spironolactone and endocrine dysfunction. Ann. Intern. Med. 1976; 85: 630-6.
30. Carvol P, Michael P, Menard J et al. Anti-androgenic effect of spironolactone; mechanism of action. Endocrinology 1975; 97: 52-8.
31. Abrams GA, Concato J, Fallon MB. Muscle cramps in patients with cirrhosis. Am. J. Gastroenterol. 1996; 91: 1363-6.
32. Arroyo V, Ginès P, Gerbes AL et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996; 23 (1): 164-76.
33. Arroyo V, Epstein M, Gallus G et al. Refractory ascites in cirrhosis; mechanism and treatment. Gastroenterol. Int. 1989; 2: 195-207.
34. Epstein M. Peritoneovenous shunt in the management of ascites and the hepatorenal syndrome. Gastroenterology 1982; 82: 790-6.
35. Blendis LM, Greig PD, Langer B et al. Renal and hemodynamic effect of the peritoneovenous shunt for intractable hepatic ascites. Gastroenterology 1979; 77: 250-7.
36. Epstein M. Peritoneovenous shunt in the management of ascites and the hepatorenal syndrome. Gastroenterology 1982; 82: 790-9.
37. Blendis LM, Harrison JE, Russell DM et al. Effects of peritoneovenous shunting on body composition. Gastroenterology 1986; 90: 127-34.
38. Greig PD, Langer NB, Blendis LM et al. Complications after peritoneovenous shunting for ascites. Am. J. Surg. 1980; 139: 125-31.
39. Le Veen HH, Ahmed N, Hutto RB et al. Coagulopathy post peritoneovenous shunt. Ann. Surg. 1987; 205: 305-11.
40. Markey W, Payne JA, Strauss A. Hemorrhage from esophageal varices after placement of the LeVeen shunt. Gastroenterology 1979; 77: 341-3.
41. Le Veen HH, Vujic I, D'Ovidio NJ, Hutto RB. Peritoneovenous shunt occlusion. Etiology, diagnosis, therapy. Ann. Surg. 1984; 200: 212-23.
42. Smajda C, Tridart D, Franco D. Recurrent ascites due to central venous thrombosis after peritoneojugular (Le Veen) shunt. Surgery 1986; 100: 535-40.
43. Fulenwider JT, Galambos JD, Smith RB et al. Le Veen versus Denver peritoneovenous shunt for intractable ascites. Arch. Surg. 1986; 121: 351-5.
44. Ginès A, Planas R, Angeli P et al. Treatment of patients with cirrhosis and refractory ascites using LeVeen shunt with titanium tip: comparison with therapeutic paracentesis. Hepatology 1995; 22: 124-31.
45. Stanley MM. PVS in patients with cirrhotic ascites and end-stage renal failure. Am. J. Kidney Dis. 1985; 6: 185-7.
46. Bories P, Garcia Compeam D, Michel H et al. The treatment of refractory ascites by the LeVeen shunt. A multi-centre controlled trial (57 patients). J. Hepatol. 1986; 3: 212-18.
47. Ginès P, Arroyo V, Vargas V et al. Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites. N. Engl. J. Med. 1991; 325: 829-35.
48. Stanley MM, Ochi S, Lee KK et al. Peritoneovenous shunting as compared with medical treatment in patients with alcoholic cirrhosis and massive ascites. N. Engl. J. Med. 1989; 321: 1632-8.
49. Salerno F, Badalamenti S, Incerti P et al. Repeated paracentesis and IV albumin infusion to treat 'tense' ascites in cirrhotic patients: A safe alternative therapy. J. Hepatol. 1987; 5: 102-8.
50. Titó Ll, Ginès P, Arroyo V et al. Total paracentesis associated with intravenous albumin in the management of patients with cirrhosis and ascites. Gastroenterology 1990; 98: 146-51.
51. Sola R, Vila C, Andreu M et al. Total paracentesis with dextran-40 versus diuretics in the treatment of ascites in cirrhosis. A randomized controlled trial. J. Hepatol. 1994; 20: 282-8.
52. Ginès P, Titó Ll, Arroyo V et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988; 94: 1493-502.
53. Simon DM, McCain JR, Bonkovsky HL et al. Effects of therapeutic paracentesis on systemic and hepatic hemodynamics and on the renal and hormonal function. Hepatology 1988; 7: 423-9.
54. Panos MZ, Moore K, Vlavianos P et al. Single, total paracentesis for tense ascites: sequential hemodynamic changes and right atrial size. Hepatology 1990; 11: 662-7.
55. Luca A, García-Pagán JC, Bosch J et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology 1995; 22 (3): 7753-8.
56. Pozzi M, Osculati G, Buari G et al. Time course of circulatory and humoral effects of rapid total paracentesis in cirrhotic patients with tense, refractory ascites. Gastroenterology 1994; 106: 709-19.
57. Kao HW, Rakov NE, Savage E, Reynolds TB. The effect of large volume paracentesis on plasma volume: A cause of hypovolemia? Hepatology 1985; 5: 403-7.
58. Pinto PC, Amerian J, Reynolds TB. Large-volume paracentesis in nonedematous patients with tense ascites: Its effects on intravascular volume. Hepatology 1988; 8: 207-10.
59. Planas R, Ginès P, Arroyo V et al. Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis: Results of a randomized study. Gastroenterology 1990; 99: 1736-44.
60. Salerno F, Badalamenti S, Lorenza E et al. Randomized comparative study of hemaccel versus albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology 1991; 13: 707.
61. Bañares R, Clemente L, Santos L et al. Dextrano 70 versus albúmina como agente expansor en paracentesis evacuadoras. Resultados preliminares de un estudio aleatorizado. Gastroenterol. Hepatol. 1989; 12: 233 (In Spanish with English abstract).
62. Fassio E, Terg R, Landeire G et al. Paracentesis with Dextran 70 versus paracentesis with albumin in cirrhosis with tense ascites. Results of a randomized study. J. Hepatol. 1992; 14: 310-16.
63. Ginès A, Fernández-Esparrach G, Monescillo A et al. Randomized trial comparing albumin, Dextran-70 plus polygeline in cirrhotic patients with ascites treated with paracentesis. Gastroenterology 1996; 111: 1002-10.
64. Cabrera J, Inglada L, Quintero E et al. Large-volume paracentesis and intravenous saline: effects on the reninangiotensin system. Hepatohgy 1991; 14: 1025-8.
65. Orloff MJ. Pathogenesis and surgical treatment of intractable ascites associated with alcoholic cirrhosis. Ann. NY Acad. Sci. 1970; 170: 213.
66. Castells A, Saló J, Planas R et al. Impact of shunt surgery for variceal bleeding in the natural history of ascites in cirrhosis: a retrospective study. Hepatology 1994; 20: 584-91.
67. Elcheroth J, Vons C, Franco D. Role of surgical therapy in management of intractable ascites. World J. Surg. 1994; 18 (2): 240-5.
68. Schroeder ET, Numann PJ, Chamberllain BE. Functional renal failure in cirrhosis. Recovery after portocaval shunt. Ann. Intern. Med. 1970; 72: 923-8.
69. Shiffman ML, Jeffers L, Hoofnagle JH et al. The role of transjugular intrahepatic portosystemic shunt for treatment of portal hypertension and its complications: A conference sponsored by the National Digestive Diseases Advisory Board. Hepatology 1995; 22: 1591-7.
70. Theilmann L, Sauer P. Transjugular intrahepatic portosystemic sten shunt: results and complications. Radiology 1994; 34: 174-7.
71. Wong F, Sniderman K, Liu P et al. Transjugular intrahepatic portosystemic sten shunt: effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites. Ann. Intern. Med. 1995; 122: 816-22.
72. Ferrai H, Bjarnason H, Wegryn SA et al. Refractory ascites: early experience in treatment with transjugular portosystemic shunt. Radiology 1993; 189: 795-801.
73. Ochs A, Rössle M, Haag K et al. The transjugular intrahepatic portosystemic sten-shunt procedure for refractory ascites. N. Engl. J. Med. 1995; 332: 1192-7.
74. Somberg KA, Lake JR, Tomlanovich SJ et al. Transjugular intrahepatic portosystemic shunts for refractory ascites: assessment of clinical and hormonal response and renal function. Hepatology 1995; 21: 709-16.
75. Lebrec D, Givity N, Habengue A. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites. A randomized trial. J. Hepatol. 1996; 25: 135-44.
76. Bruno S, Borzio M, Romagnoni M et al. Comparison of spontaneous ascites reinfusion with total paracentesis with intravenous albumin infusion in cirrhotic patients with tense ascites. BMJ 1992; 304: 1655-8.
77. Smart HL, Triger DR. A randomized prospective trial comparing daily paracentesis and intravenous albumin with recirculation in diuretic refractory ascites. J. Hepatol. 1990; 10: 191-7.
78. Levy VG, Opolon P, Pauleau N, Caroli J. Treatment of ascites by reinfusion of concentrated peritoneal fluid: A review of 318 procedures in 210 patients. Postgrad. Med. J. 1975; 51: 564-7.
79. Pérez GO, Golper TA, Epstein M, Oster JR. Dialysis, hemofiltration and other extracorporeal techniques in the treatment of the renal complications of liver disease. In: Epstein M, ed. The Kidney in Liver Disease, 4th edn. Philadelphia: Hanley & Belfus Inc., 1991; 517-28.
80. Lai KN, Leung JW, Owen JW. Dialytic ultrafiltration by hemofilter in treatment of patients with refractory ascites and renal insufficiency. Am. J. Gastroenterol. 1987; 82: 665-8.
81. Bruno S, Borzio M, Romagnoni P et al. Comparison of spontaneous ascites filtration and reinfusion with total paracentesis with intravenous albumin infusion in cirrhotic patients with tense ascites. BMJ 1992; 304: 1658-65.
82. Samuel D, Farges O, Bismuth H. Long term outcome after liver transplantation. In: Arroyo V, Bosch J, Rodés J, eds. Treatments in Hepatology. Barcelona: Masson, 1995; 227-35.
83. Arroyo V, Planas R, Gaya J et al. Plasma renin activity and urinary sodium excretion as prognostic indicators in nonazotemic cirrhosis with ascites. Ann. Intern. Med. 1981; 94: 198-201.
84. Genoud E, Gonvers JJ, Schaller MD et al. Valeur prognostique du system renine-angiotensine dans la response a la restriction sodèe et le prognostique de l'ascite cirrhotique d'origine alcoolique. Schweiz. Med. Wochenschr. 1986; 116: 463-9 (in French with English abstract).
85. Llach J, Ginès P, Arroyo V et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988; 94: 482-7.
86. Tage-Jensen U, Henriksen JGH, Christensen E et al. Plasma catecholamine level and portal venous pressure as guides to prognosis in patients with cirrhosis. J. Hepatol. 1988; 6: 350-8.
87. Gonwa TA, Morris CA, Goldstein RM et al. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome-experience in 300 patients. Transplantation 1991; 24: 428-30.
88. Gonwa TA, Klintmalm GB, Jennings LS et al. Impact of pretransplant renal function on survival after liver transplantation. Transplantation 1995; 59: 361-5.
89. Seu P, Wilkinson AH, Shaked A, Busuttil BW. The hepatorenal syndrome in liver transplant recipients. Am. Surg. 1991; 57: 806-9.
90. Navasa M, Feu F, Bosch J et al. Systemic, splanchnic and humoral changes after orthotopic liver transplantation (OLT) in cirrhosis (abstract). J. Hepatol. 1991; 13: S55.
91. Rimola A, Gavaler JS, Schade RR et al. Effects of renal impairment on liver transplantation. Gastroenterology 1987; 93: 148-56.